Camp4 Therapeutics Corporation (CAMP)
| Market Cap | 260.43M +755.4% |
| Revenue (ttm) | 4.22M +40.2% |
| Net Income | -107.24M |
| EPS | -2.18 |
| Shares Out | 62.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,055 |
| Open | 4.180 |
| Previous Close | 4.140 |
| Day's Range | 4.030 - 4.300 |
| 52-Week Range | 1.410 - 7.750 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 9.92 (+139.04%) |
| Earnings Date | Aug 13, 2026 |
About CAMP
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015... [Read more]
Financial Performance
In 2025, Camp4 Therapeutics's revenue was $3.50 million, an increase of 436.50% compared to the previous year's $652,000. Losses were -$80.40 million, 55.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CAMP stock is "Strong Buy." The 12-month stock price target is $9.92, which is an increase of 139.04% from the latest price.
News
Camp4 Therapeutics reports Q2 EPS (58c), consensus (21c)
Reports Q2 revenue $1.78M, consensus $1.89M. “Having secured regulatory clearance in both Australia and Argentina, we are now focused on initiating our first-in-human Phase 1/2 clinical trial of CMP-0...
Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler
Piper Sandler raised the firm’s price target on Camp4 Therapeutics (CAMP) to $15 from $12 and keeps an Overweight rating on the shares. The firm notes Camp4 ended Q2 with…
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth ...
Camp4 Therapeutics Quarterly report: Q2 2026
Camp4 Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Camp4 Therapeutics Earnings release: Q2 2026
Camp4 Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The trial will enroll at ...
Camp4 Therapeutics Registration statement: Registration filing
Camp4 Therapeutics filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's adv...
Camp4 Therapeutics receives Australia TGA clearance for CMP-002 trial
CAMP4 Therapeutics (CAMP) announced that it has received clearance from Australia’s Therapeutic Goods Administration, or TGA, and local Human Research Ethics Committee to initiate the Company’s Phase ...
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through seco...
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regula...
X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board
X4 Pharmaceuticals (XFOR) announced the appointment of Kelly Gold to the company’s board of directors effective July 1, adding strong strategic and financial expertise. Gold will serve as an independe...
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regula...
Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Camp4 Therapeutics (CAMP) to Overweight from Neutral with a price target of $9, up from $5. The shares are undervalued on the potential for CMP-002 in SYNGAP1-related disorder,…
Camp4 Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and approved the election of directors, auditor ratification, and an equity plan amendment. Stockholders could submit questions, and forward-looking statements were addressed with reference to risk factors in SEC filings.
Camp4 Therapeutics initiated with a Buy at Chardan
Chardan analyst Keay Nakae initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $6.50 price target The firm cites the potential of the company’s novel regRNA-targeting strategy for…
New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity
Canadian GoldCamps says Mercator resampling returned gold in 82% of samples, confirming mineralization continuity and new high-grade targets for 2026 work.
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model
Camp4 Therapeutics reports Q1 EPS (32c), consensus (21c)
Reports Q1 revenue $1.29M, consensus $1.12M. “We have made significant progress year-to-date against our goal of bringing a potential first-in-class treatment for SYNGAP1-related disorder into the cli...
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGA...
Camp4 Therapeutics Quarterly report: Q1 2026
Camp4 Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Camp4 Therapeutics Earnings release: Q1 2026
Camp4 Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscover...
Camp4 Therapeutics Proxy statement: Proxy filing
Camp4 Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Camp4 Therapeutics Proxy statement: Proxy filing
Camp4 Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.